Sterility Concerns Lead to Recall of Compounded GLP-1 Drugs, Highlighting Broader Safety Issues

A recent recall of 22 vials of compounded tirzepatide injections due to sterility concerns underscores ongoing safety issues with compounded glucagon-like peptide-1 (GLP-1) receptor agonists. Unlike FDA-approved versions, compounded GLP-1s do not undergo the same rigorous premarket review for safety, effectiveness, and quality, raising concerns about their continued presence on the market after drug shortages have been resolved.